• Proveris Scientific names Daniel Tereau as President and CEO

  OINDP instrument and testing specialist Proveris Scientific, which was acquired by Investindustrial earlier this year, has announced that experienced life sciences executive Daniel Tereau is the company’s new President and Chief Executive Officer 2026. Tereau was most… [Read more . . .]

• Leyden Labs reveals that it has acquired RIGImmune and announces results from a Phase 1 trial of RIG-101 intranasal antiviral

  Leyden Laboratories has announced that it acquired intranasal RNA therapy developer RIGImmune sometime earlier this year. The company also reported results from a Phase 1 study of RIGImmune’s RIG-101, an intranasal innate immune modulator for… [Read more . . .]

• MannKind and Rose Pharma partner on development of ROSE-010 Technosphere GLP-1 DPI for weight loss

  MannKind and Rose Pharma have announced a collaboration agreement that gives Rose a worldwide license for development of its ROSE-010 rapid-acting GLP-1 as an inhaled therapy for weight loss using MannKind’s Technosphere dry powder technology.… [Read more . . .]

• AirNexis announces results from Haisco’s Phase 2b trial of AN01 PDE3/4 inhibitor DPI in patients with COPD

  AirNexis Therapeutics has announced that a Chinese Phase 2b study of AN01 (HSK39004) PDE3/4 inhibitor DPI in COPD patients that was conducted by Haisco Pharmaceutical met its primary endpoint. AirNexis launched in early 2026 with… [Read more . . .]

• Rezubio initiates Phase 1 trial of RZ-520 inhaled therapy in development for the treatment of respiratory diseases

  Chinese biotech Rezubio has announced the initiation of a Phase 1 PK/PD study of RZ-520, which Rezubio describes as “a novel inhaled therapeutic drug candidate for the treatment of chronic respiratory diseases.” According to Rezubio,… [Read more . . .]

• FDA grants Fast Track designation to Liquidia’s Yutrepia treprostinil DPI for the treatment of Raynaud’s phenomenon in systemic sclerosis

• Chiesi announces European regulatory submissions for LGWP formulations of BDP/FF/GB and BDP/FF MDIs

• Aptar announces that Nanopharm will provide development services for Aceso’s ACT-101 antisense oligonucleotide for CF

• Copley Scientific launches Inhalytix+ v2.0 and Critical Flow Controller TPK 200iX

• Chinese NMPA approves Milestone and Everest’s Cardamyst etripamil nasal spray for the treatment of PSVT

More news . . .